[{"id":"2f64949b-56d2-4517-8a8d-e52f407e983c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03559413","created_at":"2021-01-18T17:31:11.379Z","updated_at":"2024-07-02T16:35:27.228Z","phase":"Phase 1/2","brief_title":"Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL","source_id_and_acronym":"NCT03559413","lead_sponsor":"University Children's Hospital Tuebingen","biomarkers":" CD8 • CD4","pipe":" | ","alterations":" CD8 expression • CD4 expression","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • CD4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zyclara (imiquimod)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-12-04"},{"id":"495ae210-14e3-4dc2-9bda-5e696bcb61a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT06056804","created_at":"2023-11-19T01:16:40.961Z","updated_at":"2024-07-02T16:35:28.894Z","phase":"Phase 2","brief_title":"Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer","source_id_and_acronym":"NCT06056804","lead_sponsor":"Beijing Friendship Hospital","biomarkers":" CD8 • CD163 • CD4 • CD68 • CD86","pipe":" | ","alterations":" CD163 expression • CD4 expression","tags":["CD8 • CD163 • CD4 • CD68 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD163 expression • CD4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • capecitabine • Zadaxin (thymalfasin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2023-11-17"},{"id":"5c915e24-3c58-4466-86ca-c8a54189cd55","acronym":"Zirconipi","url":"https://clinicaltrials.gov/study/NCT03313323","created_at":"2021-01-18T16:21:49.240Z","updated_at":"2025-02-25T14:26:48.454Z","phase":"Phase 2","brief_title":"Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma","source_id_and_acronym":"NCT03313323 - Zirconipi","lead_sponsor":"Amsterdam UMC, location VUmc","biomarkers":" CTLA4 • CD4","pipe":" | ","alterations":" CTLA4 expression • CD4 expression","tags":["CTLA4 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTLA4 expression • CD4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 02/16/2017","start_date":" 02/16/2017","primary_txt":" Primary completion: 02/15/2022","primary_completion_date":" 02/15/2022","study_txt":" Completion: 02/15/2022","study_completion_date":" 02/15/2022","last_update_posted":"2021-04-15"},{"id":"2d54c98d-2a85-4b12-b07f-d3d93dbe593d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03446911","created_at":"2021-01-18T16:59:43.511Z","updated_at":"2024-07-02T16:37:13.467Z","phase":"Phase 1/2","brief_title":"Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery","source_id_and_acronym":"NCT03446911","lead_sponsor":"Amsterdam UMC, location VUmc","biomarkers":" PD-L1 • CD8 • PD-1 • CD4 • FOXP3","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression • CD4 expression • FOXP3 expression","tags":["PD-L1 • CD8 • PD-1 • CD4 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression • CD4 expression • FOXP3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 05/01/2020","primary_completion_date":" 05/01/2020","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2018-02-27"},{"id":"ca926512-6064-4fa7-b79f-522281599998","acronym":"","url":"https://clinicaltrials.gov/study/NCT00049504","created_at":"2021-01-18T00:05:09.256Z","updated_at":"2024-07-02T16:37:22.043Z","phase":"Phase 2","brief_title":"Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer","source_id_and_acronym":"NCT00049504","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD8 • HLA-DRB1 • PTPRC • NCAM1 • HLA-B • HLA-C • NCR1","pipe":" | ","alterations":" CD8 expression • Chr del(5q) • CD4 expression","tags":["CD8 • HLA-DRB1 • PTPRC • NCAM1 • HLA-B • HLA-C • NCR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • Chr del(5q) • CD4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 01/01/2002","start_date":" 01/01/2002","primary_txt":" Primary completion: 03/01/2011","primary_completion_date":" 03/01/2011","study_txt":" Completion: 02/01/2014","study_completion_date":" 02/01/2014","last_update_posted":"2017-05-17"}]